Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.52 |
| ▸ | APC | P25054 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512270 | 0.94 | APC (0.55) | QRFPRAPCKEAP1OPRM1OPRD1 | |
| SCHEMBL29939679 | 0.94 | APC (0.55) | QRFPRAPCKEAP1OPRM1OPRD1 | |
| SCHEMBL30617832 | 0.89 | QRFPR (0.57) | QRFPRAPCFOLH1 | |
| SCHEMBL29504883 | 0.88 | NAALAD2 (0.55) | NAALAD2QRFPR | |
| SCHEMBL30997458 | 0.87 | QRFPR (0.54) | QRFPROPRM1OPRD1 | |
| SCHEMBL31479983 | 0.87 | FOLH1 (0.43) | NAALAD2QRFPRAPCKEAP1FOLH1 | |
| SCHEMBL29350857 | 0.86 | MME (0.57) | QRFPR | |
| SCHEMBL31031528 | 0.85 | NAALAD2 (0.55) | NAALAD2OPRM1OPRD1 | |
| SCHEMBL30861236 | 0.85 | OPRD1 (0.53) | KEAP1OPRM1OPRD1 | |
| SCHEMBL30880911 | 0.85 | NAALAD2 (0.57) | NAALAD2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259183-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOF | Larimar Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126029-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOF | LARIMAR THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |